Good performance status, serum albumin ≥ 3.5 mg/dL, and response to first-line therapy emerged as prognostic factors for better survival in advanced NSCLC patients in resource-limited settings, where sophisticated molecular testing and advanced therapies are often unavailable. This evidence concerns the gene ALB and non-small cell lung carcinoma.